Archive
EARLY MOVERS - Loxo Oncology shares skyrocket on news of Eli Lilly acquisition; DXC Technology to buy Luxoft Holding
Also in the frame in pre-market is electric car titan Tesla and media group CBS Corp
Company
Bristol-Myers Squibb Co
NYSE:BMY
Bristol-Myers Squibb Co is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
79 stories · page 2 of 4
Biotech CEOs see Bristol-Myers' $74B acquisition of Celgene as a win
The tie-up underlines how the largest pharmaceutical companies are eager to embark on the acquisition trail to boost pipelines
Sareum Holdings shares soar as Hybridan spotlights read-across from big US pharma takeover deal
The small-cap broker’s analysts noted that Bristol-Myers Squibb has agreed to acquire Celgene for US$74bn, with the combined entity to have six expected near-term product launches
EARLY MOVERS: Celgene rallies as Bristol-Myers offers to buy cancer drug company
Airline stocks decline after Delta lowered its outlook for revenue growth
Mirati Therapeutics shares tumble on release of Phase 2 trial data for lung cancer treatment
The study was evaluating Mirati’s therapy sitravatinib in combination with Bristol-Myers Squibb’s groundbreaking drug Opdivo as a method for treating non-small cell lung cancer
Bristol-Myers Squibb shares fall after FDA delays approval for lung cancer therapy
The EU is also requesting more information on overall survival rates for patients in the study
How Genprex took an abandoned pipeline drug and turned it into Oncoprex, an innovative treatment for non-small cell lung cancer
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Bristol-Myers Squibb makes $12 million investment in Compugen, sets up research partnership
New trials will evaluate the safety and tolerability of Compugen’s COM701 in combination with Bristol-Myers' immune checkpoint inhibitor Opdivo in patients with advanced cancerous tumors
EARLY MOVERS: Square shares fall and Compugen shares surge on Bristol-Myers Squibb investment as stock markets in turmoil
Also in focus before the New York bell is taxi app titan Uber and Hurricane Michael
EARLY MOVERS: Bristol-Myers Squibb shares spurt higher on FDA news, but Tesla Inc shares lose power
Also in focus in US pre-market trade was Teva Pharmaceutical Industries Ltd and Deere & Company
Merck's 2Q earnings beat Street with sales turbocharged by cancer drug Keytruda
Drug giant raised its full-year guidance to a range of US$4.22 and US$4.30 a share compared with US$4.16 to US$4.28 a share expected last quarter
Bristol-Myers Squibb's 2Q earnings beat Street on healthy sales of its blockbuster cancer drug Opdivo
The drugmaker raised its full-year forecast to between US$3.55 and US$3.65 per share, taking up the top and bottom end of its previous forecast by US$0.20 per share
PRE-MARKET MOVERS: Smartphone giant BlackBerry leaps ahead of bell after quarterly results
CarMax Inc and PayPal Holdings Inc are also stocks trending ahead of the Wall Street start..
Small-Cap Snapshot: Corindus inks deal to branch out to Japan, Funko investors file class-action suit
The medical-device company received approval to market its CorPath GRX system in Japan
Bristol Myers Squibb showcases positive results of new Phase 3 study evaluating cancer drug Opdivo
The study's results suggest Opdivo extends progression free survival in certain lung cancer patients when taken in combination with chemo and a drug called Yervoy
Jounce Therapeutics shares plunge on scant details about its Phase 1/2 ICONIC trial
The biotech's preliminary data evaluates its lead drug candidate JTX-2011
Bristol-Myers beats 1Q estimates, guides higher for full-year 2018 on drug approvals
The drug giant reported earnings of $0.94 per share on revenue of US$5.2bn. The consensus estimate from analysts was US$0.85 per share on revenue of US$5.2bn
Wall Street ends on a high as reporting season cheer continues
Wall Street shares closed Tuesday higher; The Dow Jones added over 213 points
Investments and investor services
US benchmarks close higher as earnings season points to strong growth
US stocks advanced as traders remain bullish about the corporate earnings season
Bristol-Myers falls after Citi analyst says Pfizer not interested in buying the drugmaker
New York pharma giant is also working with Harvard researchers to develop fibrotic disease treatments